PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1731822
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1731822
Global Immunodiagnostics Market to Reach US$29.9 Billion by 2030
The global market for Immunodiagnostics estimated at US$24.6 Billion in the year 2024, is expected to reach US$29.9 Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Immunodiagnostics Reagents, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$16.8 Billion by the end of the analysis period. Growth in the Immunodiagnostics Instruments segment is estimated at 2.7% CAGR over the analysis period.
The U.S. Market is Estimated at US$6.7 Billion While China is Forecast to Grow at 6.3% CAGR
The Immunodiagnostics market in the U.S. is estimated at US$6.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.0 Billion by the year 2030 trailing a CAGR of 6.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.
Global Immunodiagnostics Market - Key Trends & Drivers Summarized
Why Are Immunodiagnostics Critical in Early Disease Detection and Monitoring?
Immunodiagnostics are laboratory-based diagnostic techniques that utilize antigen-antibody interactions to detect and quantify biomarkers in patient samples such as blood, urine, or saliva. These tests are crucial in diagnosing infectious diseases, autoimmune disorders, hormonal imbalances, cancer, and allergies. They are widely used in hospitals, diagnostic laboratories, and research institutions for their high specificity, sensitivity, and rapid turnaround time. As healthcare systems focus on preventive diagnostics and early intervention, immunodiagnostic tools are becoming foundational in modern medical testing.
Their utility spans both qualitative and quantitative applications, ranging from enzyme-linked immunosorbent assays (ELISA) and chemiluminescent immunoassays (CLIA) to lateral flow immunoassays used in point-of-care testing. With increasing demand for decentralized diagnostics and home-based health monitoring, immunodiagnostics are also being integrated into compact platforms and multiplexed test formats, making them more accessible and efficient in both clinical and non-clinical settings.
How Are Technological Innovations Enhancing Test Accuracy and Speed?
The immunodiagnostics market is undergoing rapid transformation through advancements in assay chemistry, biosensor design, and detection systems. High-throughput automated analyzers, nanomaterial-enhanced immunoassays, and digital immunoassay platforms are significantly improving test sensitivity and multiplexing capabilities. These innovations are allowing for the simultaneous detection of multiple biomarkers from a single sample, which is particularly beneficial in cancer screening, autoimmune profiling, and infectious disease panels.
Additionally, smartphone-linked devices and microfluidic lab-on-chip technologies are expanding point-of-care applications, especially in resource-limited settings. AI-driven algorithms are being integrated into diagnostic software to improve interpretation accuracy and clinical decision-making. Moreover, the incorporation of fluorescence, electrochemical, and photonic detection techniques is enhancing the analytical performance of immunodiagnostic tools, making them more reliable for personalized and precision medicine.
Which Applications and Regions Are Driving Demand for Immunodiagnostic Testing?
Key clinical applications include infectious disease diagnostics (e.g., HIV, hepatitis, COVID-19), oncology markers (e.g., PSA, CA125), cardiovascular risk profiling (e.g., troponins), and autoimmune panels (e.g., ANA, rheumatoid factor). Hospitals and diagnostic labs remain the largest end-users, followed by home healthcare, academic research centers, and biopharmaceutical companies. The demand for immunodiagnostic testing is especially strong in chronic disease management and post-surgical monitoring.
North America dominates due to the presence of leading diagnostic firms, high healthcare spending, and a strong regulatory framework. Europe follows with growing emphasis on preventive diagnostics and screening programs. Asia-Pacific is the fastest-growing region, driven by rising healthcare access in countries like China and India, increasing awareness of early diagnosis, and expanding insurance coverage. Africa and Latin America are also seeing growing adoption as infrastructure and disease surveillance programs improve.
The Growth in the Immunodiagnostics Market Is Driven by Several Factors…
The growth in the immunodiagnostics market is driven by several factors including the global rise in chronic and infectious diseases, advances in assay automation and sensitivity, and increasing demand for rapid and accurate diagnostics. Technological improvements in multiplex immunoassays, lab-on-chip systems, and AI-enhanced test platforms are expanding both clinical and point-of-care use. Regulatory approvals for new biomarkers and test kits are also contributing to market expansion.
From an end-use perspective, the rising adoption of home-based testing, growing investment in personalized medicine, and the integration of immunodiagnostics in drug development workflows are fueling demand. Government screening programs, especially in oncology and infectious diseases, and the expansion of decentralized lab networks are also key growth contributors. As diagnostic precision becomes increasingly vital in modern healthcare, immunodiagnostics will continue to be a cornerstone of laboratory medicine worldwide.
SCOPE OF STUDY:
The report analyzes the Immunodiagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Product Type (Reagents, Instruments, Software & Services); Technology (Enzyme-linked Immunosorbent Assay, Chemiluminescence Immunoassay, Fluorescent Immunoassay, Radioimmunoassay, Other Technologies); Application (Infectious Diseases, Oncology & Endocrinology, Bone & Mineral Diseases, Autoimmune Disorders, Cardiac Biomarkers, Drug Monitoring, Other Applications); End-Use (Hospitals, Clinical Laboratories, Academic & Research Institutes, Other End-Uses)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 34 Featured) -
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.
We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.
As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.
To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!
APRIL 2025: NEGOTIATION PHASE
Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.
JULY 2025 FINAL TARIFF RESET
Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.
Reciprocal and Bilateral Trade & Tariff Impact Analyses:
USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.
Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.
COMPLIMENTARY PREVIEW
Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.